As per MRFR analysis, the US Plasma Therapy Market Size was estimated at 0.93 (USD Billion) in 2023. The US Plasma Therapy Market Industry is expected to grow from 1.3(USD Billion) in 2024 to 3.5 (USD Billion) by 2035. The US Plasma Therapy Market CAGR (growth rate) is expected to be around 9.421% during the forecast period (2025 - 2035).
The US Plasma Therapy Market is witnessing significant growth fueled by the increasing adoption of regenerative medicine and a heightened focus on innovative treatment options for various medical conditions. One of the key market drivers is the rising prevalence of chronic diseases and orthopedic conditions, which has led to a growing demand for effective therapies like plasma therapy.
Health practitioners in the US are increasingly recognizing the benefits of utilizing platelet-rich plasma for treatment, especially in sports medicine and cosmetic procedures, adding to the therapy's appeal. Additionally, advancements in technology are paving the way for improved processing techniques for plasma extraction, enhancing the safety and efficacy of treatments.
The US healthcare landscape is also supportive of plasma therapies, as regulatory bodies streamline the approval process for such innovations, thus promoting market growth. Opportunities exist in the development of new applications of plasma therapy, particularly in treating conditions like osteoarthritis and tendon injuries.
The ongoing research efforts, including clinical trials, present avenues for expanding the therapeutic potential of plasma therapy, highlighting its versatility and reliability. Recent trends indicate a shift towards more personalized and minimally invasive treatment methods, which aligns with patient preferences in the US.
The healthcare industry is moving towards integrating plasma therapy into standard treatment protocols, reflecting not only its therapeutic effectiveness but also the growing patient awareness and demand for such solutions. Furthermore, physician training programs are increasingly incorporating plasma therapy, ensuring that practitioners are well-equipped to offer these advanced treatment options to their patients continuously.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The US Plasma Therapy Market Industry is witnessing a significant increase in the acceptance of plasma therapy across various medical fields, including orthopedics, dermatology, and oncology. The American Academy of Orthopaedic Surgeons indicates that over 2 million Americans undergo orthopedic procedures each year, with a growing trend towards minimally invasive techniques that include plasma therapy.
Additionally, the approval of innovative therapy products by the Food and Drug Administration, such as platelet-rich plasma treatments for injury healing and surgery recovery, is paving the way for broader market adoption. This growing acceptance is likely to contribute to the projected growth in the US Plasma Therapy Market Industry, with an expected compound annual growth rate of 9.421%.
Moreover, the National Institutes of Health reports that conditions treated by plasma therapy have seen an increase in patient outcomes, which bolsters the credibility and demand for such therapies in the US healthcare system.
The US Plasma Therapy Market Industry is being driven by the rising incidence of chronic diseases, particularly in conditions such as arthritis, diabetes, and heart disease. The Centers for Disease Control and Prevention report that approximately 60% of adults in the US have at least one chronic disease, showing a clear need for innovative treatment solutions.
Platelet-rich plasma therapy, an effective intervention to manage pain and promote healing in musculoskeletal injuries, is becoming more prominent in clinical practices. This high prevalence of chronic conditions suggests an increased demand for effective treatment modalities, ultimately fueling growth in the US Plasma Therapy Market Industry.
Technological advancements in plasma processing and the development of new methodologies are significant drivers of growth in the US Plasma Therapy Market Industry. Innovations in blood extraction and plasma separation techniques are enhancing the effectiveness and safety of plasma therapies.
Regulatory advancements have encouraged investment in Research and Development by companies such as Terumo Blood and Cell Technologies and CSL Behring, leading to more efficient processing systems and improved product offerings. According to the American Red Cross, there has been a 10% increase in blood donations over the past five years, which further increases the availability of plasma for therapeutic applications.
These technological advancements are thus essential for meeting the growing demand for plasma therapies in the US market.
There is an increased focus on regenerative medicine within the healthcare sector, which is significantly impacting the US Plasma Therapy Market Industry. This field emphasizes healing and tissue regeneration, where plasma therapy plays a critical role.
The National Institutes of Health reports that regenerative medicine is projected to grow to $50 billion by 2026, indicating a strong trend toward therapies that enhance the body's natural healing processes. Major research institutions like Johns Hopkins University are investing heavily in regenerative medicine research, leading to novel applications of plasma therapy in treating conditions such as sports injuries and degenerative diseases.
This shift towards regenerative approaches further stimulates the demand for plasma therapies in the United States.
The US Plasma Therapy Market focuses on various applications that leverage the therapeutic potential of plasma-derived products. Among these applications, Orthopedics stands out due to the increasing prevalence of musculoskeletal disorders, which has catalyzed the adoption of plasma therapy for tissue healing and regeneration.
The utilization of platelet-rich plasma (PRP) injections in Orthopedics is gaining traction, as these treatments are known to expedite recovery times and enhance the healing of injuries, particularly in the knee, shoulder, and other joints. In Dermatology, the use of plasma therapy has emerged as a promising avenue for addressing skin conditions, as well as improving aesthetic outcomes.
Procedures such as PRP facials have become popular for their potential to rejuvenate the skin, enhance texture, and reduce the signs of aging. This segment benefits from a heightened consumer awareness of non-invasive treatments, further driving interest in plasma-based solutions.
The Dental field is also witnessing an uptick in the use of plasma therapy, particularly in procedures aimed at promoting healing after oral surgeries or tooth extractions. Plasma-derived products are considered valuable in improving the outcomes of dental procedures, as they may help reduce recovery times and the likelihood of complications, thus gaining acceptance among dental professionals.
Cardiology is another critical area where plasma therapy is gaining attention, particularly for its potential role in enhancing heart function and recovery after cardiac events. The healing properties of plasma products may provide innovative ways to support cardiovascular health, addressing a significant and growing concern in the US as lifestyle-related heart diseases continue to rise.
Overall, the segmentation of the US Plasma Therapy Market across these applications reflects a broader trend toward personalized, targeted therapies that harness the natural healing capabilities of the body. The potential for plasma therapies to complement existing medical treatments presents major opportunities for growth and innovation in these fields, affirming their importance in the landscape of modern medicine.
As the market continues to evolve, ongoing research and clinical trials will likely shape the adoption levels and applications of plasma therapies across these critical health domains. The expansion of these applications could be further supported by favorable regulatory conditions and increasing investments in research and development activities aimed at enhancing clinical understanding and efficacy.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The US Plasma Therapy Market is characterized by a diverse range of types, with Platelet Rich Plasma (PRP), Platelet Rich Fibrin (PRF), and Bone Marrow Aspirate being notable segments. PRP has gained significant traction in the field of regenerative medicine due to its ability to promote healing and tissue regeneration, making it a preferred option in various clinical applications, including orthopedics and dermatology.
On the other hand, PRF, which provides a higher concentration of growth factors than PRP, has been recognized for its effectiveness in tissue repair, especially in dental and surgical settings, often leading to reduced healing times. Meanwhile, Bone Marrow Aspirate, known for its rich stem cell content, plays a crucial role in treating orthopedic injuries and chronic conditions, offering considerable potential for joint repair and enhancement of recovery processes.
The growth of these segments is supported by advancements in technologies and increased acceptance of non-invasive treatments among patients in the US. This market diversity highlights the importance of tailored therapies for specific medical needs, driving innovation and improved patient outcomes in the US Plasma Therapy Market.
The US Plasma Therapy Market is characterized by diverse end use applications, which significantly influence its growth trajectory. Hospitals play a critical role as they cater to a substantial volume of patients requiring plasma therapies for various medical conditions, particularly in emergency and surgical settings.
Ambulatory Surgical Centers are gaining traction due to their ability to provide specialized plasma treatments in a more efficient and cost-effective manner, appealing to patients looking for alternatives to traditional hospital settings. Clinics are also pivotal in delivering outpatient plasma therapy services, offering tailored treatment plans to meet individual patient needs.
The increasing prevalence of chronic diseases and rising geriatric population in the US are prime drivers enhancing the demand for plasma therapy across these end use categories. Furthermore, advancements in plasma extraction and treatment technologies present significant opportunities for growth in this market.
As these end use segments evolve, they will continue to shape the dynamics of the US Plasma Therapy Market, impacting market growth and driving innovations in patient care.
The US Plasma Therapy Market is making significant strides within the healthcare industry, particularly in its Procedure Type segment, which encompasses both invasive and non-invasive approaches. The demand for these procedures is on the rise, driven by their effectiveness in treating a variety of conditions, including musculoskeletal disorders and skin rejuvenation.
Invasive procedures, known for their direct application of plasma, often yield immediate results, making them popular among patients seeking quick recovery solutions. Conversely, non-invasive methods are seeing increased traction due to their appeal for patients wary of surgical interventions, providing substantial benefits with minimal downtime.
This segmentation reflects a growing trend towards personalized patient care, as practitioners increasingly tailor treatments to individual needs. The US Plasma Therapy Market is positioned to adapt as healthcare providers and patients alike prioritize safety, efficacy, and convenience in treatment options.
By focusing on these procedures, the market is expected to capitalize on the ongoing advancements in technology and research, creating a dynamic environment for future growth and innovation. Key factors such as an aging population, increasing healthcare expenditure, and a rise in chronic diseases contribute to the evolving landscape of the US Plasma Therapy Market.
The US Plasma Therapy Market has become increasingly competitive, driven by various factors including rising demand for plasma-derived therapies, advancements in technology, and an expanding patient population in need of specific treatments. The market features a complex landscape characterized by numerous players, each vying for market share by leveraging their unique strengths and capabilities.
This competition is further intensified by ongoing research and development initiatives aiming to improve existing therapies and create new applications for plasma products. Key players are focusing on strategic partnerships, collaborations, and innovations to enhance their market presence and address an array of therapeutic areas that plasma therapy covers.
Octapharma has established a significant footprint in the US Plasma Therapy Market, primarily recognized for its high-quality plasma products. The company's strengths lie in its robust manufacturing capabilities and a strong commitment to research and development, which ensures a consistent supply of innovative therapies tailored to meet the needs of patients.
Octapharma’s presence in the US is bolstered by its extensive distribution network, which enables it to deliver critical therapies efficiently. Furthermore, its dedication to patient safety and product efficacy has fostered trust among healthcare providers and patients alike, solidifying its competitive position in an increasingly crowded market.
LFB Group also plays a vital role in the US Plasma Therapy Market, focusing on the development and production of a diverse range of plasma-derived medicinal products, including immunoglobulins and clotting factors. The company’s strengths include its advanced biotechnology platform and commitment to quality, ensuring that its products meet stringent regulatory standards.
Additionally, LFB Group is actively pursuing growth strategies through mergers and acquisitions, which enhance its market presence and expand its product offerings in the US. By fostering strategic partnerships and investing in innovation, LFB Group positions itself to respond quickly to market demands, thereby reinforcing its status as a prominent player in the US plasma therapy landscape.
The US Plasma Therapy Market has seen significant developments recently, particularly with the ongoing research into the efficacy of convalescent plasma for treating various conditions, including COVID-19. Companies like Grifols and CSL Behring have expanded their manufacturing capabilities to meet the rising demand for immunoglobulin therapies.
Additionally, in July 2023, Takeda Pharmaceuticals announced its plan to acquire a competitor, enhancing its product portfolio in plasma-derived therapies. Meanwhile, Abbott launched a new diagnostic test in August 2023 to streamline blood component collection, aiding firms like Octapharma and LFB Group in optimizing their processes.
With increasing investments in Research and Development, sectors involving Plasma Therapy are projected to grow, alongside rising valuations due to the surge in autoimmune diseases and hemophilia treatment requirements. Over the past couple of years, regulations have tightened around plasma source management, impacting operations across the market.
In November 2022, the FDA released new guidelines affecting the quality and safety standards for plasma collections, elevating operational benchmarks for companies like Kedrion Biopharma and AMAG Pharmaceuticals. These dynamics reflect a continually evolving landscape in the US Plasma Therapy Market.
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2018 | 0.93(USD Billion) |
| MARKET SIZE 2024 | 1.3(USD Billion) |
| MARKET SIZE 2035 | 3.5(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 9.421% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Billion |
| KEY COMPANIES PROFILED | Octapharma, LFB Group, Shire Pharmaceuticals, AMAG Pharmaceuticals, Biotest AG, Grifols, Takeda Pharmaceuticals, Cangene Corporation, Baxter International, CSL Behring, HUMAN BIOLOGICS, AbbVie, Terumo BCT, Sanofi, Kedrion Biopharma |
| SEGMENTS COVERED | Application, Type, End Use, Procedure Type |
| KEY MARKET OPPORTUNITIES | Growing demand for regenerative medicine, Rising prevalence of chronic diseases, Advancements in treatment technologies, Expanding applications in sports medicine, Increasing investment in clinical research |
| KEY MARKET DYNAMICS | growing adoption in orthopedic surgeries, increasing investments in R&D, rising prevalence of chronic conditions, expanding cosmetic treatment applications, favorable regulatory environment |
| COUNTRIES COVERED | US |
Frequently Asked Questions (FAQ) :
The US Plasma Therapy Market is expected to be valued at 1.3 billion USD in 2024.
By 2035, the US Plasma Therapy Market is anticipated to reach a valuation of 3.5 billion USD.
The market is expected to grow at a CAGR of 9.421% from 2025 to 2035.
Orthopedics is expected to hold the largest market share, valued at 0.52 billion USD in 2024.
The Dermatology segment is valued at 0.34 billion USD in 2024.
Major players include Octapharma, LFB Group, Shire Pharmaceuticals, and Grifols among others.
The Cardiology application segment is expected to grow from 0.2 billion USD in 2024 to 0.54 billion USD by 2035.
By 2035, the Dental segment is expected to reach a value of 0.63 billion USD.
Challenges include regulatory hurdles and the need for advanced technologies in treatment methods.
The market is expected to exhibit significant growth across all applications including Orthopedics, Dermatology, Dental, and Cardiology.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Analyst Explore the profile of garvit vyas, one of our esteemed authors at market research future, and access their expert research contributions in the field of market research and industry analysis
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
